Anzeige
Mehr »
Mittwoch, 10.09.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14X6S | ISIN: US15870P3073 | Ticker-Symbol: 2I3
Tradegate
10.09.25 | 07:36
5,700 Euro
-0,87 % -0,050
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CHAMPIONS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CHAMPIONS ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,5505,70009:15
5,5505,70008:59

Aktuelle News zur CHAMPIONS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.07.CHAMPIONS ONCOLOGY, INC. - 10-K, Annual Report1
23.07.Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $57 Million269Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced...
► Artikel lesen
21.07.CHAMPIONS ONCOLOGY, INC. - 8-K, Current Report1
21.07.Champions Oncology, Inc.: Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025233HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report...
► Artikel lesen
18.07.Champions Oncology Names New CEO1
18.07.Champions Oncology names Rob Brainin as new CEO5
18.07.Champions Oncology, Inc.: Champions Oncology Announces Appointment of New CEO467HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today...
► Artikel lesen
08.07.Champions Oncology lanciert Plattform für radiopharmazeutische Dienstleistungen, erweitert seine Isotopen-Lizenz und screent über 30 PDX-Modelle308Erweitertes Angebot ermöglicht integrierte radiopharmazeutische Studien unter Einsatz von klinisch relevanten Isotopen und hochgradig charakterisierten PDX-Tumormodellen HACKENSACK...
► Artikel lesen
CHAMPIONS ONCOLOGY Aktie jetzt für 0€ handeln
08.07.Champions Oncology startet Plattform für radiopharmazeutische Dienstleistungen2
08.07.Champions Oncology, Inc.: Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models828Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions...
► Artikel lesen
28.04.Champions Oncology, Inc.: Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House288HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical...
► Artikel lesen
28.04.Champions Oncology secures license for radionuclide studies1
28.04.Champions Oncology sichert Lizenz für Radionuklidstudien-
24.04.Champions Oncology, Inc.: Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine526HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of...
► Artikel lesen
17.03.CHAMPIONS ONCOLOGY, INC. - 10-Q, Quarterly Report1
11.03.Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million313HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...
► Artikel lesen
06.03.Champions Oncology, Inc.: Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025334HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will...
► Artikel lesen
18.02.Champions Oncology, Inc.: Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting136HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance...
► Artikel lesen
08.01.Champions Oncology erweitert sein klinisch-bioanalytisches Leistungsportfolio mit neuer Technologie und zusätzlichem Führungsexperten360HACKENSACK, NJ / ACCESSWIRE / 8. Januar 2025 / Champions Oncology, Inc. (NASDAQ: CSBR), eine führende technologiegestützte Organisation im Bereich der onkologischen Forschung, die spezielle Testdienstleistungen...
► Artikel lesen
08.01.Champions Oncology, Inc.: Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership259HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1